Astellas suffers as US Prograf sales slump
This article was originally published in Scrip
Astellas' group net sales fell by 7% to ¥461.7 billion ($5.74 billion) in the first half to 30 September, dragged down by plunging sales of its top global product, the immunosuppressant Prograf (tacrolimus).
You may also be interested in...
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.